NGNE (Neurogene) ROE % Adjusted to Book Value: -37.30% (As of Mar. 2026)


NGNE Neurogene Inc NGNE
12 GF Score
Price $32.05
! 4 Warning Signs
View Full Analysis

What is Neurogene ROE % Adjusted to Book Value?

Neurogene NGNE +5.26% 12 ROE % Adjusted to Book Value is -37.30% as of Mar. 2026. GuruFocus rates NGNE with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

Neurogene's ROE % for the quarter that ended in Mar. 2026 was -49.23%. Neurogene's PB Ratio for the quarter that ended in Mar. 2026 was 1.32. Neurogene's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -37.30%.

Neurogene ROE % Adjusted to Book Value Related Terms

Neurogene ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Neurogene's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurogene ROE % Adjusted to Book Value Chart

Neurogene Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 -134.55 -27.78 -26.18

Neurogene Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.15 -39.96 -32.41 -31.09 -37.30

NGNE vs SGMT, IPSC, UPB: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Neurogene's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurogene ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurogene's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Neurogene's ROE % Adjusted to Book Value falls into.


NGNE
12GF Score
Neurogene Inc NGNE
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurogene ROE % Adjusted to Book Value Calculation

Neurogene's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-31.41% / 1.20
=-26.18%

Neurogene's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-49.23% / 1.32
=-37.30%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -37.30% mean?
Neurogene (NGNE) has a ROE % Adjusted to Book Value of -37.30% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Neurogene and its competitors.
Is Neurogene's ROE % Adjusted to Book Value too high?
Neurogene's current ROE % Adjusted to Book Value is -37.30%. Overall, Neurogene has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Neurogene's ROE % Adjusted to Book Value compare to SGMT and IPSC?
Neurogene's ROE % Adjusted to Book Value of -37.30% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Neurogene and its competitors. Neurogene's current ROE % Adjusted to Book Value is -37.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurogene stock overvalued right now?
Neurogene (NGNE) has a current ROE % Adjusted to Book Value of -37.30%. The current ROE % Adjusted to Book Value is -37.30%. Neurogene's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Neurogene (NGNE), the current ROE % Adjusted to Book Value is -37.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurogene Business Description

Other Exchanges UU8:Germany
Address 535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
12GF Score

Get the complete analysis for NGNE

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.05
Price